UroGen Pharma
Market Cap
US$520.1m
Last Updated
2020/07/15 00:06 UTC
Data Sources
Company Financials +
Executive Summary
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Share Price & News
How has UroGen Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: URGN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-3.4%
URGN
0.8%
US Biotechs
1.5%
US Market
1 Year Return
-26.7%
URGN
30.0%
US Biotechs
6.9%
US Market
Return vs Industry: URGN underperformed the US Biotechs industry which returned 26.1% over the past year.
Return vs Market: URGN underperformed the US Market which returned 5.3% over the past year.
Shareholder returns
| URGN | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.4% | 0.8% | 1.5% |
| 30 Day | -10.9% | 11.4% | 5.9% |
| 90 Day | 7.1% | 23.6% | 17.9% |
| 1 Year | -26.7%-26.7% | 31.2%30.0% | 9.2%6.9% |
| 3 Year | 30.9%30.9% | 33.0%28.5% | 36.4%27.5% |
| 5 Year | n/a | -4.2%-9.6% | 64.9%47.0% |
Price Volatility Vs. Market
How volatile is UroGen Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 hours ago | Simply Wall St
Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Deliver On Growth Plans?1 month ago | Simply Wall St
What Kind Of Shareholder Owns Most UroGen Pharma Ltd. (NASDAQ:URGN) Stock?2 months ago | Simply Wall St
Does UroGen Pharma's (NASDAQ:URGN) Share Price Gain of 40% Match Its Business Performance?Valuation
Is UroGen Pharma undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: URGN ($23.71) is trading below our estimate of fair value ($141.16)
Significantly Below Fair Value: URGN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: URGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: URGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate URGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: URGN's PB Ratio (3.3x) is in line with the US Biotechs industry average.
Next Steps
Future Growth
How is UroGen Pharma forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
67.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: URGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: URGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: URGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: URGN's revenue (61.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: URGN's revenue (61.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: URGN is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has UroGen Pharma performed over the past 5 years?
-57.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: URGN is currently unprofitable.
Growing Profit Margin: URGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: URGN is unprofitable, and losses have increased over the past 5 years at a rate of -57.8% per year.
Accelerating Growth: Unable to compare URGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: URGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: URGN has a negative Return on Equity (-80.75%), as it is currently unprofitable.
Next Steps
Financial Health
How is UroGen Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: URGN's short term assets ($121.9M) exceed its short term liabilities ($14.2M).
Long Term Liabilities: URGN's short term assets ($121.9M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: URGN is debt free.
Reducing Debt: URGN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: URGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: URGN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 57.3% each year.
Next Steps
Dividend
What is UroGen Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate URGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate URGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if URGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if URGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of URGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Liz Barrett (58yo)
1.5yrs
Tenure
US$25,900,823
Compensation
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology ...
CEO Compensation Analysis
Compensation vs Market: Liz's total compensation ($USD25.90M) is above average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Insufficient data to compare Liz's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$25.90m | 0.72% $3.7m | |
| CFO & Secretary | 1.92yrs | US$1.35m | 0.032% $167.8k | |
| Chief Medical Officer | 2.58yrs | US$800.91k | 0.084% $436.3k | |
| 1.5yrs | US$699.77k | no data | ||
| Senior Director of Investor Relations | 2.5yrs | no data | no data | |
| Senior Director of Communications | no data | no data | no data | |
| Marketing Director | no data | no data | no data | |
| Executive Vice President of Research & Development and Technical Operations | 0.33yr | no data | no data | |
| Chief Commercial Officer | 0.33yr | no data | no data | |
| Executive Vice President of Regulatory Affairs & Quality | 0.33yr | no data | no data | |
| Chief Development Officer | 0.33yr | no data | no data | |
| Senior Vice President of Business Development | 1.83yrs | no data | no data |
1.5yrs
Average Tenure
55.5yo
Average Age
Experienced Management: URGN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.5yrs | US$25.90m | 0.72% $3.7m | |
| Independent Director | 3.25yrs | US$332.70k | 0.074% $384.5k | |
| Independent Director | 3.17yrs | US$317.70k | 0.068% $355.6k | |
| Independent Director | 2.75yrs | US$335.20k | no data | |
| Independent Director | 4.58yrs | US$320.20k | no data | |
| Independent Chairman | 7.58yrs | US$472.70k | 1.1% $5.7m | |
| Independent Director | 7.17yrs | US$317.78k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2yrs | US$312.70k | no data |
3.2yrs
Average Tenure
62.5yo
Average Age
Experienced Board: URGN's board of directors are considered experienced (3.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.
Top Shareholders
Company Information
UroGen Pharma Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: UroGen Pharma Ltd.
- Ticker: URGN
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$520.082m
- Shares outstanding: 21.94m
- Website: https://www.urogen.com
Number of Employees
Location
- UroGen Pharma Ltd.
- 400 Alexander Park
- Princeton
- New Jersey
- 8540
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| URGN | NasdaqGM (Nasdaq Global Market) | Yes | Ordinary Shares | US | USD | May 2017 |
| UR8 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 2017 |
| 0XOD | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | USD | May 2017 |
Biography
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company’s lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/15 00:06 |
| End of Day Share Price | 2020/07/14 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.